Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification

Journal of Clinical Oncology

Volumn 27, Issue 7, 2009, Pages 1034-1040

  De Bernardi, Bruno ^a   Gerrard, Mary ^a   Boni, Luca ^a   Rubié, Herve ^a   Cañete, Adela ^a   Cataldo, Andrea D ^a   Castel, Victoria ^a   De Lacerda, Ana Forjaz ^a   Ladenstein, Ruth ^a   Ruud, Ellen ^a   Brichard, Benédicte ^a   Couturier, Jerome ^a   Ellershaw, Caroline ^a   Munzer, Caroline ^a   Bruzzi, Paolo ^a   Michon, Jean ^a   Pearson, Andrew D J ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; TECHNETIUM; VINCRISTINE;

ADRENAL GLAND; ARTICLE; BLEEDING; BONE METASTASIS; BONE RADIOGRAPHY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISSEMINATED CANCER; DRUG FATALITY; DRUG TREATMENT FAILURE; FEMALE; GENE AMPLIFICATION; HUMAN; INFANT; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LIVER FAILURE; LUNG INFECTION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROBLASTOMA; NEWBORN; ONCOGENE; ONCOGENE MYCN; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEIZURE; SEPSIS; SURGICAL MORTALITY; SYMPTOMATOLOGY; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; WOUND HEALING IMPAIRMENT;

DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM REGRESSION, SPONTANEOUS; NEUROBLASTOMA; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 61449196709     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.5877     Document Type: Article

References (22)

1. De Bernardi B, Di Tullio MT, Cordero di Montezemolo L, et al: Neuroblastoma under one year of age: Clinical aspects and management, in Lampert F, Cordero di Montezemolo L, Pession A (eds): Contributions to Oncology, vol 41: Cancer in the First Year of Life. Basel, Switzerland, Karger, 1990, pp 118-128
2. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 27:374-378, 1971
3. De Bernardi B, Pianca C, Boni L, et al: Disseminated neuroblastoma (stage IV and IV-S) in the first year of life: Outcome related to age and stage: Italian Cooperative Group on Neuroblastoma. Cancer 70:1625-1633, 1992
4. Brodeur GM, Pritchard J, Berthold F, et al: Revision of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11:1466-1477, 1993
5. National Cancer Institute: Neuroblastoma treatment. http://www.cancer. gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional/page6
6. Katzenstein HM, Bowman LC, Brodeur GM, et al: Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience. J Clin Oncol 16:2007-2017, 1998
7. Strother D, Shuster JJ, McWilliams N, et al: Results of Pediatric Oncology Group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 17:254-259, 1995
8. Schmidt ML, Lukens JN, Seeger RC, et al: Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 18:1260-1268, 2000
9. Nickerson HJ, Matthay KK, Seeger RC, et al: Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 18:477-486, 2000
10. Hero B, Simon T, Horz S, et al: Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis? Med Pediatr Oncol 35:683-687, 2000
11. Minard V, Hartmann O, Peyroulet MC, et al: Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: Results of the French Society of Pediatric Oncology. Br J Cancer 83:973-979, 2000
12. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372, 1999
13. Navarro S, Amann G, Beiske K, et al: Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neu-roblastic tumors: A histopathologic study of Localized Neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol 24:695-699, 2006
14. Hsu LL, Evans AE, D'Angio GJ: Hepatomegaly in neuroblastoma stage 4S: Criteria for treatment. Med Ped Oncol 27:521-528, 1996
15. Ambros IM, Benard J, Boavida M, et al: Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21:2077-2084, 2003
16. Cecchetto G, Mosseri V, De Bernardi B, et al: Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Paediatric Oncology Neuroblastoma Group. J Clin Oncol 23:8483-8489, 2005
17. Guglielmi M, De Bernardi B, Rizzo A, et al:Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: Does it affect the clinical course? J Clin Oncol 14:1537-1544, 1996
18. Common Terminology Criteria for Adverse Events Version 3.0 (v3.0): Cancer Therapy Evaluation Program. http://ctep.cancer.gov/reporting/ctc.html
19. Schemper M, Terry L, Smith A: A note on quantifying follow up in studies of failure time. Control Clin Trials 17:343-346, 1996
20. De Bernardi B, Nicolas B, Boni L, et al: Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21:1592-1601, 2003
21. Cañete A, Gerrard M, Rubie H, et al: Dismal survival for infants with MYCN amplified metastatic neuroblastoma in spite of an intensified treatment: The SIOPEN experience. J Clin Oncol doi:10.1200./JCO.2007.14.5839
22. Combaret V, Bergeron C, Noguera R, et al: Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol 23:8919-8920, 2005